Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Lonza’s GlycoConnect Technology for Best-in-Class ADCs: Emerging Clinical Insights

Lonza’s GlycoConnect Technology for Best-in-Class ADCs: Emerging Clinical Insights

12:30 pm - Tuesday 13th October 2026

Exploring how Lonza’s GlycoConnect and HydraSpace technologies enable ADCs with best-in-class therapeutic potential
Sharing clinical development insights on the rapidly expanding and advancing pipeline of Lonza’s GlycoConnect technology based partnered ADC assets
Discussing technology expansion towards high-DAR and dual payload ADCs

Speakers:

Anette Sommer

Anette Sommer

Head of Biochemistry

Lonza